Home › NDC Lookup › RxCUI directory › RxCUI 793741

Sodium polystyrene sulfonate 250 MG/ML Oral Suspension [Kionex] — RxCUI 793741

RxNorm drug concept · Semantic branded drug
RxCUI 793741 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI793741
Official nameSodium polystyrene sulfonate 250 MG/ML Oral Suspension [Kionex]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asKionex 15 GM per 60 ML Oral or Rectal Suspension; Kionex 15 GM in 60 mL Oral or Rectal Suspension
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)1,560 prescriptions · 15 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Sodium Polystyrene Sulfonate: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Think of it as a tiny sponge that travels through your intestines. It grabs onto extra potassium in your gut and carries it out of your body in your stool — it never actually enter...
  • What exactly is sodium polystyrene sulfonate doing in my body?
  • It can take anywhere from several hours to a few days to meaningfully lower your potassium levels — so it's definitely not a quick fix. If your potassium is dangerously high right...
  • How long does it take to work, and do I need to take it long-term?
📖 Read our full Sodium Polystyrene Sulfonate guide →

🕸️ Concept Web — How Sodium polystyrene sulfonate 250 MG/ML Oral Susp... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Sodium polystyrene sulfonate 250 MG/ML Oral Suspension [Kionex] RxCUI 793741

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Sodium polystyrene sulfonate 56512
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Kionex 284757
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Sodium polystyrene sulfonate Oral Suspension 375287
    • Sodium polystyrene sulfonate Oral Liquid Product 1159944
    • Sodium polystyrene sulfonate Oral Product 1159945
    • Sodium polystyrene sulfonate Oral Suspension [Kionex] 793740
    • Kionex Oral Liquid Product 1171401
    • Kionex Oral Product 1171402
    • Oral Suspension 316969
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Sodium polystyrene sulfonate 250 MG/ML Oral Suspension SCD · 313072
  • Sodium polystyrene sulfonate 250 MG/ML SCDC · 316714
  • Sodium polystyrene sulfonate Oral Suspension SCDF · 375287
  • Sodium polystyrene sulfonate Oral Liquid Product SCDG · 1159944
  • Sodium polystyrene sulfonate Oral Product SCDG · 1159945

Brand-Name Concepts

  • Sodium polystyrene sulfonate 250 MG/ML [Kionex] SBDC · 793739
  • Sodium polystyrene sulfonate Oral Suspension [Kionex] SBDF · 793740
  • Kionex Oral Liquid Product SBDG · 1171401
  • Kionex Oral Product SBDG · 1171402
  • Kionex BN · 284757

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 793741 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
62559-0356-01 10 BOTTLE in 1 CASE (62559-356-01) / 60 mL in 1 BOTTLE (625... Kionex ANI Pharmaceuticals, Inc. 2024-05-03
Observed labelers: ANI Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$0.3270
Range $0.3270–$0.3270 · middle 50% $0.3270–$0.3270 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.